Inventor · disambiguated record
Michael Dussiot
Also filed as: DUSSIOT MICHAEL · DUSSIOT MICHAËL
1 granted patent·8 pending applications·0 citations·filing 2013–2022
10Inventor score
Files withINST NAT SANTE RECH MED4CELGENE CORP3INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE)1INSTITUT NAT DE LA SANTE ET DE LA RECHECHE MEDICALE INSERM1
Top patents by PatentIndex Score
9 records- 0150US2019049469A1Biomarker for use in treating anemiaCELGENE CORP·Filed 2018·Application pending·0 cites
- 0249US2025011792A1Irap inhibitors for use in the treatment of inflammatory diseasesINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 0348US2015276766A1Biomarker for use in treating anemiaCELGENE CORP·Filed 2013·Application pending·0 cites
- 0447US2025003993A1Methods and kits for identifying and quantifying storage-induced microerythrocytesINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 0545US2022073626A1Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancerINSTITUT NAT DE LA SANTE ET DE LA RECHECHE MEDICALE INSERM·Filed 2020·Application pending·0 cites
- 0637US2015266950A1Methods for treating anemiaCELGENE CORP·Filed 2013·Application pending·0 cites
- 0728US2015197574A1Use of transferrin receptor antagonist for the treatment of thalassemiaINST NAT SANTE RECH MED·Filed 2013·Application pending·0 cites
- 0822US2018031579A1Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such diseaseINSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECH MÉDICALE)·Filed 2016·Application pending·0 cites
- 0921US10111896B2Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapseINST NAT SANTE RECH MED·Filed 2015·Granted Oct 30, 2018·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Michael Dussiot files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →